18F-FET is a radiolabelled amino acid that may be used as PET radiopharmaceutical in neuro-oncology. 18F-FET PET has been demonstrated to be useful in the differential diagnosis between brain tumours and non-neoplastic lesions and between low-grade and high-grade gliomas. Integration of 18F-FET PET into surgical planning allows better delineation of the extent of resection beyond margins visible with standard MRI. For biopsy planning, 18F-FET PET is particularly useful in identifying malignant foci within non-contrast-enhancing gliomas. 18F-FET PET may also improve the radiation therapy planning in patients with gliomas. This metabolic imaging method may be useful to evaluate treatment response in patients with gliomas and it improves the differential diagnosis between brain tumours recurrence and post-treatment changes. Furthermore, 18F-FET PET may provide useful prognostic information in high-grade gliomas.
Overall, based on literature data 18F-FET PET may provide additional diagnostic information compared to standard MRI in neuro-oncology.
Keywords18F-FET Fluoroethyltyrosine PET Brain tumours Glioma Neuro-oncology
European Association for Neuro-Oncology
Magnetic resonance imaging
Positron emission tomography
Response Assessment in Neuro-Oncology (RANO)
Conflicts of Interest: The authors declare that they have no conflicts of interest.